Kymab is a biopharmaceutical company which discovers and develops human monoclonal antibody therapeutics. The Company focuses on using the Kymouse platform for the discovery, development, and commercialization of monoclonal antibodies to difficult and novel drug targets in various therapeutic areas. Its pipeline products cover immuno-oncology, immunology, and opportunistic therapeutic spaces.
Latest funding size
Time since last funding
|a year ago|
|Woodford Investment Management, Malin, Bill & Melinda Gates Foundation, Hepalink, Wellcome Trust, ORI Healthcare Fund, Woodford Patient Capital, Malin Corporation plc|